FDA approves GSK's BCMA drug, marking a rocky return to cancer for the British giant

Jason Mast

Editor

Despite concerns on both safety and efficacy, the FDA approved GlaxoSmithKline’s multiple myeloma drug belantamab mafodotin, deciding that for the sickest patients the benefits outweighed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves GSK's BCMA drug, marking a rocky return to cancer for the British giant

Jason Mast

Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche CEO warns that tariffs could impact dealmaking

Merck is ‘well-positioned’ on Keytruda ahead of threatened pharma tariffs, CEO says

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

FDA ap­proves GSK's BC­MA drug, mark­ing a rocky re­turn to can­cer for the British gi­ant

Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

FDA approves GSK's BCMA drug, marking a rocky return to cancer for the British giant